All the Therapeutic System Drugs
Serotonin 2C Receptor Agonist. Lorcaserin Hydrochloride (hemihydrate) 10.4 mg. FILM COAT. TABS.: 60
The recommended dose 10 mg ×2/d, with / without food. Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, the drug should be discount. See lit.
Indic. as an adjunct to a reduced-calorie diet and incr. physic. activity for chron. weight manag. in adult pts. with an initial BMI of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condit. (e.g., hypertens., dyslipidemia, type 2 diabet.).
Uric Acid Production Inhibitor. Febuxostat 80 mg. F.C. TABS.:28. 80 mg ×1/d no regard to
meals. If serum uric acid is > 6 mg/dL
(357 μmol/L) after 2-4 wks., 120 mg
×1/d may be consid. Retest ser. uric
acid after 2 wks. Gout flare prophylaxis
of at least 6 mths. is recom.
Tmt. of chronic hyperuricaemia in cond.
where urate deposition has already
occurred (include. a history, presence of,
tophus and/or gouty arthritis).
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly. The dose should be incr. to 3.0 mg dly. in increm. of 0.6 mg with at least one week interv. to improve GI tolerabil. If escal. to the next dose step is not tolerated for two consec. wks., consider discount. tmt. Dly. doses higher than 3.0 mg are not recomm.
As an adjun. a reduced-calorie diet and incr. phys. active. for weight manag. in adult pts. with an init. BMI of ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid. such as dysglycaemia (pre-diab. or type 2 diab. mell.), hypertens. or dyslipidaemia, and who have failed a prev. weight manag. intervent. Tmt. should be discount. after 12 wks. on the 3.0 mg/day dose if pts. have not lost at least 5% of their init. bdy. wt.
Lipase Inhibitor. Orlistat 120 mg. CAPS: 7, 21, 42, 84 x 120 mg.
Adults and child over 12 yrs:
1 cap. 3 x dly.
In conjunct. with mildly hypocaloric diet
for obese patients with a BMI greater or
equal to 30 kg/m2, or overweight patients
(BMI >28 kg/m2) with assoc. risk factors.
C/I: Hypersens., chron. malabsorpt.
syndr., cholestasis, lact.